Preview

Siberian journal of oncology

Advanced search

Laboratory indices and survival of urinary bladder cancer patients

Abstract

Current laboratory techniques were used for evaluation of tumor markers, growth factors, angiogenesis, intercellular adhesion in biological fluids of 349 patients with nonmusculo-invasive urinary bladder cancer (264 patients had a single tumor and 285 presented with multiple tumor foci). An analysis was made of the correlation between four indices most closely related with the number of tumor foci in the bladder, and patient survival. The log-rank test found a correlation between the levels of UBC, sICAM, TPS, p185 in biological fluids, and survival (Plog-rank<0,05). The values of UBC in urine and sICAM in blood serum affect overall, cancer-specific, recurrence-free survivals of patients with either a single tumor focus or multiple tumor foci in the bladder. TPS blood levels affect the same survivals but only in patients with a single tumor focus. As regards p185, the level of this protein has a significant impact on all the calculated survivals of patients with nonmusculo-invasive bladder cancer. Multivariate analysis including all the four indices, with Cox proportional hazards regression model, found that a high blood level of p185 is an unfavourable prognostic factor for recurrence-free survival: with p185 concentration <4,43 ng/ml, 5-year recurrence-free survival of patients with a single tumor focus in the bladder was 95,9 % and with p185≥4,43 ng/ml it was 64,1 %; in patients with multiple tumor foci it was 83,6 % with p185<5,7 ng/ml and 30,0 % with p185≥5,7 ng/ml.

About the Author

L. A. Derzhavets
N.N. Alexandrov National Cancer Centre of Belarus, Minsk
Russian Federation


References

1. Аль-Шукри С.Х., Корнеев И.А. Общие принципы лечения больных раком мочевого пузыря. Значение клинических, гистологических и биологических факторов прогноза для выбора метода лечения // Практическая онкология. 2003. Т. 4, № 4. С. 204–213.

2. Гуменецкая Ю.В., Попов А.М., Карякин О.Б. и др. Результаты комбинированного лечения (трансуретральной резекции опухоли с последующей дистанционной лучевой терапией) у больных мышечноинвазивным раком мочевого пузыря // Сибирский онкологический журнал. 2012. № 2 (50). С. 6–10.

3. Державец Л.А. Значимость лабораторных показателей для определения количества опухолевых очагов у больных немышечно-инвазивным раком мочевого пузыря // Современные технологии в медицине. 2012. № 3. С. 36–40.

4. Троянов А.В. Диагностика и прогнозирование рецидива немышечно-инвазивного рака мочевого пузыря при помощи клинических методов и FISH-анализа // Онкоурология. 2012. № 3. С. 43–50.

5. Халмурзаев О.А., Матвеев В.Б., Петерсон С.Б. и др. Влияние повторной трансуретральной резекции на частоту рецидивов у больных немышечно-инвазивным раком мочевого пузыря // Онкоурология. 2012. № 2. С. 66–71.

6. Dalbagni G. Bladder cancer: Restaging TUR reduces recurrence and progression risk // Nat. Rev. Urol. 2010. Vol. 12 (7). Р. 649–650.

7. Hall C., Chang S., Dalbagni G. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta,T1 and Tis): 2007 update // J. Urol. 2007. Vol. 178. P. 2314–2330.

8. Sobin L.H., Gospodarowicz M.K., Wittekind Ch.E. TNM classification of malignant tumors, 7th ed. Wiley-Blackwell, Oxford, 2009. P. 310.


Review

For citations:


Derzhavets L.A. Laboratory indices and survival of urinary bladder cancer patients. Siberian journal of oncology. 2013;(4):12-16. (In Russ.)

Views: 611


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1814-4861 (Print)
ISSN 2312-3168 (Online)